Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2025-11-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
江苏泰和律师事务所关于金陵药业股份有限公司2025年第三次临时股东大会的法律意见书
Regulatory Filings
2025-11-13 Chinese
金陵药业股份有限公司关于修订《公司章程》及相关议事规则的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding the revision of the company's Articles of Association (公司章程) and related rules of procedure. It includes extensive legal and governance-related content such as changes to the board structure, shareholder rights, management responsibilities, and corporate governance rules. The document is not a financial report, earnings release, or capital update. It is not a simple announcement of a report but contains substantive governance content. Therefore, it fits best under the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-10-27 Chinese
金陵药业股份有限公司第九届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 21st meeting of the 9th Board of Directors of Jinling Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results on various proposals such as amendments to company bylaws and approval of the 2025 third quarter report. The document does not contain the full third quarter report itself but references that the detailed report is published elsewhere on October 28, 2025. The document is relatively short (1558 characters) and serves as an official announcement of board meeting decisions rather than a full financial or management report. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2025-10-27 Chinese
金陵药业股份有限公司监事会关于第九届监事会第二十次会议相关事项的审核意见
Audit Report / Information Classification · 95% confidence The document is an audit opinion from the Supervisory Board of Jinling Pharmaceutical Co., Ltd. regarding the review of the company's Q3 2025 quarterly report and retrospective adjustments to financial data due to business combinations under common control. It references compliance with accounting standards and regulatory requirements, and provides an audit opinion on the financial statements and report. The document is not the full quarterly report itself but an audit or supervisory review opinion related to it. Given the focus on audit opinions and review of financial data adjustments, this fits the category of Audit Report / Information (AR). The document length is short but contains substantive audit opinions, not merely an announcement or certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). 9M 2025
2025-10-27 Chinese
董事会议事规则
Governance Information Classification · 100% confidence The document is titled '金陵药业股份有限公司董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors of Jinling Pharmaceutical Co., Ltd.' The content details the structure, powers, meeting procedures, proposal rules, decision-making rules, post-meeting matters, and implementation of board resolutions. It is a governance document outlining internal rules and procedures for the board of directors, referencing relevant laws and company articles of association. There is no financial data, no audit or financial report, no announcement of voting results, no management changes, no earnings or capital updates, and no legal proceedings. This document fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-10-27 Chinese
金陵药业股份有限公司关于召开2025年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 third extraordinary general meeting of shareholders for Jinling Pharmaceutical Co., Ltd. It includes details about the meeting time, location, agenda items (such as amendments to the company charter and meeting rules), voting procedures, registration requirements, and proxy authorization forms. There is no financial data or report content, only an announcement of the meeting and instructions for shareholders. The document length is 3421 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of a Proxy Solicitation & Information Statement (PSI), as it provides materials sent to shareholders to inform and request votes for the meeting.
2025-10-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.